Autoimmune Diseases  >>  Olumiant (baricitinib)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Olumiant (baricitinib) / Eli Lilly
NCT01398475: A Relative Bioavailability and Food Effect Study of New Formulations

Completed
1
15
RoW
LY3009104
Eli Lilly and Company, Incyte Corporation
Chronic Inflammatory Disorder, Arthritis, Rheumatoid
09/11
09/11

Download Options